2023 World Conference on Lung Cancer (Posters)-EP07.04. High-Risk Clinicopathologic and Genomic Features of Recurrence in Stage I Lung Adenocarcinoma

EP07.04. High-Risk Clinicopathologic and Genomic Features of Recurrence in Stage I Lung Adenocarcinoma - PDF(Abstract)

Pdf Summary

This study aimed to identify clinicopathologic and genomic features associated with recurrence in patients who underwent surgery for stage I lung adenocarcinoma (LUAD). The researchers reviewed a thoracic database and included 672 patients with pathologic stage I LUAD who underwent surgery from 2010 to 2020. They performed next-generation sequencing on all patients and excluded those with a history of lung cancer, neoadjuvant or adjuvant therapy, incomplete resection, or mortality within 90 days. Recurrence was determined using imaging and/or pathology, with molecular testing when necessary. <br /><br />Out of the 672 patients included, 99 (14.7%) had a recurrence. The median time to recurrence was 27 months. In their analysis, the researchers found that higher maximum standardized uptake value (SUVmax), sublobar resection, and more aggressive pathologic features of the tumor, including micropapillary/solid histologic subtypes, poor/undifferentiated grade, lymphovascular invasion (LVI), visceral pleural invasion (VPI), and spread through air spaces (STAS), were associated with recurrence. Alterations in MYC and RB1 genes were also associated with recurrence. <br /><br />After adjusting for various factors, the researchers found that recurrence was associated with increased SUVmax, sublobar resection, LVI, and alterations in MYC and RB1 genes. Pathologic stage did not remain significant in the analysis. They developed a prediction model for recurrence based on the multivariable analysis and found that its performance was good. <br /><br />The study concludes that aggressive clinicopathologic features like LVI and genomic alterations in MYC and RB1 increase the risk of recurrence in stage I LUAD. The researchers suggest the need for further studies to identify effective adjuvant therapies for this high-risk population.

Asset Subtitle

Cameron Fick

Meta Tag

Speaker Cameron Fick

Topic Early-Stage NSCLC: Progress in Pathology

Keywords

clinicopathologic features

genomic features

recurrence

surgery

stage I lung adenocarcinoma

standardized uptake value

sublobar resection

lymphovascular invasion

MYC gene

RB1 gene